

# HTAi Interest Group on Assessment of Vaccination Programmes

## Steering Committee – November 2016

### **Kristen Chelak BSc Pharm, MSc, RPh (CADTH Alternate)**



Kristen Chelak holds an MSc. in the Control of Infectious Diseases from the London (UK) School of Hygiene & Tropical Medicine and a BSc. in Pharmacy from the University of British Columbia. She practiced as a community pharmacist for several years before joining CADTH in 2008. Since joining CADTH, Kristen has been involved in a number of infectious disease HTA projects. In her current role as Manager, Program and Policy Development she leads a team focused on the development of horizon scans, environmental scans, and therapeutic reviews for pharmaceuticals including, but not limited to, those used in the prevention and treatment of infectious diseases. Vaccines continue to be an area of interest for Kristen.

[kristenc@cadth.ca](mailto:kristenc@cadth.ca) (613) 226-2553

### **Karen Facey, PhD**



Karen Facey is an Honorary Member of the Faculty of Public Health and Honorary Reserach Fellow at the University of Edinburgh. She has worked as a statistician for pharmaceutical companies and the UK medicines regulatory agency. In 2000 she setup the first national HTA Agency in Scotland and since 2003 has been an independent consultant. She has been active in HTAi for the past decade, chairing its Policy Forum and helping to found the Interest Groups for Patient/Citizen Involvement in HTA and Regulatory-HTA. She is keen to promote “full HTA” to ensure optimal organisation of health services.

Woodlands Lodge, Buchanan Castle Estate, Drymen G63 0HX UK  
[k.facey@btinternet.com](mailto:k.facey@btinternet.com) Landline:+44 1360 660316 Cell:+44 789 414 3931

### **Ray Farkouh, PhD**



Ray Farkouh has a PhD in economics from University of North Carolina, Chapel Hill, NC, is Senior Director and Team Lead in the Vaccines Outcomes Research group of Pfizer. In this role he leads a team of 10 outcomes researchers supporting Pfizer’s Global Vaccines Portfolio. The team focuses on modeling infectious diseases, conducting cost-effectiveness analyses and designing and conducting burden of illness studies.

Pfizer Inc, 500 Arcola Rd, Collegeville, PA 19426, USA  
[rfarkouh@pfizer.com](mailto:rfarkouh@pfizer.com) Landline: +1 484-865-6638 Cell: +1 919-931-6873

### **James Harris, MPhil**



James manages the Health Economics team at PHARMAC, New Zealand’s agency that funds vaccines, pharmaceuticals and devices in hospitals and community. James’ background is in health funding, market access, and epidemiology.

### **Shunya Ikeda MD, MSc, PhD**



Shunya Ikeda is Professor of Public Health at International University of Health and Welfare in Narita, Japan. He is a physician with a degree in Health Policy and Management. His main research areas include Health Technology Assessment and Vaccination Policy. He serves as a member of the advisory committee to the Japanese Ministry of Health, Labour and Welfare on the vaccination policy.

IUHW Narita Campus, 4-3 Kozunomori, Narita-city, Chiba 286-8686, Japan  
shunya@iuhw.ac.jp

### **Silvie Jerabkova, PhD**



Silvie Jerabkova is undertaking a PhD in the valuation of health technologies. She is Head of Strategic Analyses at the General Health Insurance Company of the Czech Republic, where she is founding a new applied research center. She is interested in the psychiatric care reform going on in her home country, palliative and end-of-life care issues as well as the broader issues related to vaccination policies.

silvie.jerabkova@gmail.com +42 0602 582 630


### **Marianne Klemp, NOKC**



Marianne Klemp MD PhD is Professor, Norwegian Institute of Public Health (NIPH) and Department of Pharmacology, University of Oslo, Norway. Her research interests lie within health technology assessment (HTA), comparative effectiveness research (CER) and health economic modelling research. She also has long experience from clinical research within the cancer immunology area. Her current research activities are concentrated around performing drug class reviews and the use of HTA for decision-making for both drugs and vaccines. She is a member of the EUnetHTA Joint Action 3 collaboration and is responsible for the Work Package 4 on joint production.

[Marianne.Klemp@fhi.no](mailto:Marianne.Klemp@fhi.no)

### **Andrea Poscia (Alternate to Walter Ricciardi)**



Dr. Poscia is a Researcher at the Department of Public Health of the Università Cattolica del Sacro Cuore in Rome. He is a physicians with a specialization degree in Hygiene, Preventive Medicine and Public Health. His main fields of interest are: applied epidemiology, Health Technology Assessment, Health Promotion, Vaccination, Health Services Research. He is project manager or investigator in several national and international project and he is involved in several HTA reports about drugs, vaccines and medical devices (i.e. HPV, Seasonal Influenza and

Meningococcal B Vaccines). He is co-author of 65 publications (51 articles, 14 chapters' book) and more than 100 abstracts.

### **Walter Ricciardi MD, MPH, MSc**



Professor of Hygiene and Public Health at the Catholic University of the Sacred Heart (UCSC) in Rome, in 2015 Walter Ricciardi was appointed President of the Italian National Institute of Health. He has been President of EUPHA and Member of the Executive Board of the United States NBME. Currently Member of the European Advisory Committee on Health Research to the WHO/EURO Member of the EC Expert Panel on effective ways of investing in Health, Director of the WHO Collaborating Centre for Health Policy, Governance and Leadership at the UCSC and Editor of the EJPH and Oxford Handbook of Public Health.

### **Marina Richardson (CADTH Alternate)**



Marina Richardson is a manager in clinical research at CADTH. She has worked in both the pharmaceutical and medical devices portfolio at CADTH and has an interest in health technology assessment of disease prevention products and programs. Marina has an MSc. in Epidemiology, and has experience in HTA and guideline development.

### **Christelle Saint Sardos**



Christelle Saint Sardos is the Chair of the Access Working Group of Vaccines Europe, the specialized vaccines group within the European Federation of the Pharmaceutical Industry (EFPIA). Vaccines Europe represents the major innovative research-based vaccine companies. Christelle Saint Sardos is currently Vaccines Market Access Lead Europe at Sanofi. Along her career in the pharmaceutical industry (Sanofi Pasteur MSD, Merck KGaA), Christelle Saint Sardos has developed a strong understanding of the Health Care systems in Europe, as well as an extensive experience in Market Access, Health Policy, Health technology Assessment and health Outcomes, for vaccines and other pharmaceuticals.

### **Mondher Toumi MD, MSc, PhD**



Mondher Toumi is Professor of Public Health at Aix-Marseille University and Visiting Professor at Beijing University. After working in pharmacology and public health at the University of Marseille, he was appointed Global Vice President at Lundbeck. In 2008, he founded Creativ-Ceutical, an international consulting firm dedicated to support health industries and authorities in strategic decision-making. In 2009 he was appointed Professor at Lyon University and Director of the Chair of Public Health and Market Access. He recently created the Market Access Society to promote

education and research at the interface of market access, HTA, public health and health economic assessment. Vaccines represents one of his primary areas of interest.

Public Health Department – Research Unit EA 3279, Aix-Marseille University, France.  
mondher.TOUMI@univ-amu.fr Landline: + 33 (0)4 91 39 65 00 Cell: + 33 (0)6 86 66 35 50

### **Nicolas Van de Velde, PhD (Alternate to Sharon Zhang)**



Nicolas Van de Velde holds a PhD in Epidemiology from Laval University in Canada, a MSc in Infectious Disease Modelling from Imperial college London and a degree in Chemical Civil Engineering (major in Biotechnology) from the Free University of Brussels. He has >15 years' experience in health economics, developing all types of mathematical models (e.g. static, dynamic, agent-based, optimization, budget) to assess the effectiveness and cost-effectiveness of vaccination programs. Nicolas has worked both in the academia and in the industry and is currently director in the Global Health Economics team of GSK

Vaccines in Wavre, Belgium.

GSK Vaccines, 20 Avenue Fleming, 1300 Wavre, Belgium.  
nicolas.x.van-de-velde@gsk.com Landline: +32 1085 3118 Cell: +32 475 975 842

### **Chiara de Waure, MD, MSc, PhD (Alternate to Walter Ricciardi)**



Chiara de Waure is a Medical Doctor and a Specialist in Hygiene and Preventive Medicine. She holds a Master of Science in Health Science and a PhD in Epidemiology and Biostatistics. Since November 2011 she has worked as Assistant Professor at the Institute of Public Health of the Catholic University of the Sacred Heart, Rome. Her current research is in the field of Epidemiology, Health Technology Assessment and Public Health. She is a member of the HTA working team of the Italian Society of Hygiene and Preventive Medicine and the vice-president of the Section on Health Technology Assessment of EUPHA.



**Professor Zhai (Please contact Junwen Zhou with any queries and he will translate to Prof Zhai)**



Professor Zhai is the Director of Department of Pharmacy in Peking University Third Hospital and Associate Director of Department of Pharmacy Administration and Clinical Pharmacy in Peking University. He holds senior positions in many pharmacy related association in China. He is associate editor in chief in China Pharmacy journal, and on the editorial board of several other pharmacy journals. He has a wide range research interests including therapeutic drug monitoring, evidence-based pharmacy, evidence-based guideline development, pharmacoconomics, etc. He has more than 100 publications in peer review journals. He is interested in evidence-based research to ensure appropriate use of vaccines.


**Sharon Zhang, PhD (Alternate to Nicolas Van de Velde)**



Dr. Sharon Zhang holds a Ph D degree in health economics from the National University of Singapore. Sharon is currently the Asia-Pacific Regional Director of Epidemiology and Health outcomes of GSK Vaccines. Sharon leads a team of epidemiologists and health economists to generate critical evidences in epidemiology and health economics to address the scientific data gaps and support the access of GSK vaccines across Asia-Pacific countries. Sharon is also appointed as the adjunct assistant professor in health economics by National University of Singapore, where she teaches postgraduate modules and co-supervises Ph D students in health economics.

GlaxoSmithKline Pte Ltd, 150 Beach Road, #22-00 Gateway West, Singapore 189720  
sharon.x.zhang@gsk.com Landline: +65 6232 8871 Cell: +65 9652 6558

**Junwen Zhou, MSc (Attendee for Professor Zhai)**



Junwen Zhou is a PhD student in pharmacoconomics from Aix-Marseille University and also a research analyst in the health economic and outcome research department of Creativ-Ceutical, Paris. He holds a M.Sc in Clinical Pharmacy, a B.Sc in Pharmacy and a Bachelor degree of Economics from Peking University, Beijing, China. His research interests focus on evidence synthesis research and health economic modelling. He has clinical experience in cardiology as clinical pharmacists and clinical research experience in osteoporosis and schizophrenia.

Creativ-ceutical, 215 Rue du Faubourg Saint-Honoré, 75008 Paris, France  
[izh@creativ-ceutical.com](mailto:izh@creativ-ceutical.com) Landline: : +33 (0)1 76 70 47 90 Cell: +33 (0)6 59 79 59 61